Clinical Trials

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04677595 2026-03-31

GeoMETry-C

36 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

No longer available

Phase 1 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

EGFR-mutant Non-small Cell Lung Cancer

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04926831 2025-10-16

Geometry-N

4 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04575025 2025-09-15

Special Drug Use-results Surveillance of Tabrecta Tablets

Completed

109 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04427072 2025-05-16

GeoMETry-III

Phase 3 Terminated

22 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT05703516 2025-01-14

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Recruiting

250 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04139317 2024-10-09

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

76 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

31 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03192501 2024-06-25

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Recruiting

250 enrolled

Lung Neoplasms, Neoplasms

NCT05567055 2024-06-17

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Phase 1 Terminated

3 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

373 enrolled 34 charts 5 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04816214 2024-03-05

GEOMETRY-E

Phase 3 Terminated

6 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02335944 2023-06-18

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Phase 1/2 Terminated

177 enrolled 48 charts

Carcinoma, Non-Small-Cell Lung

NCT05675683 2023-01-09

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

Completed

68 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05154344 2023-01-06

CapmATU

Completed

182 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02323126 2022-02-28

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

64 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

18 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01911507 2021-10-13

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01324479 2020-12-19

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Phase 1 Completed

131 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma

NCT02276027 2020-12-16

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

66 enrolled 18 charts

Adenocarcinoma of Lung

NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03240393 2018-07-26

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn